NCT00362713View on ClinicalTrials.gov

Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Urothelial Carcinoma
Interventions
DRUG

Ipilimumab

Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24

Trial Locations (1)

77030

The University Of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY